High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a multicenter phase II study

Annals of Oncology

Volumn 16, Issue 8, 2005, Pages 1359-1365

  Josting, Andreas ^a   Sieniawski, M ^a   Glossmann, J P ^a   Staak, O ^a   Nogova, L ^a   Peters, N ^b   Mapara, M ^c   Dorken B ^c   Ko, Y ^d   Metzner, B ^e   Kisro, J ^f   Diehl, V ^a   Engert, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Second Medical Hospital   (Germany)

^c University Children's Hospitals   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e KLINIKUM OLDENBURG   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

High dose chemotherapy; Non Hodgkin's lymphoma; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; ONDANSETRON; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 23844519678     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi248     Document Type: Article

References (33)

1. Fisher RI, Gaynor ER, Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's Lymphoma. N Engl J Med 1993; 318: 1002-1006.
2. Schmitz N. EBMT Workshop: High dose therapy in aggressive NHL. Ann Hematol 2001; 80: B24-B25.
3. Kaiser U, Uebelacker I, Abel U. Randomised study to evaluate the use of high-dose therapy as part of primary treatment for 'aggressive' lymphoma. J Clin Oncol 2002; 2: 4413-4419.
4. Koeppler H, Pflüger KH, Eschenbach I et al. Randomised comparison of CHOEP versus CHOEP/IVEP for high-grade non-Hodgkin's lymphoma: Treatment results and prognostic factor analysis in a multicenter trial. Ann Oncol 1994; 5: 49-55.
5. Haioun C, Lepage E, Gisselbrecht C. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-a group d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
6. Coiffier B, Lepage E, Brier J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
7. Habermann TM, Weller EA, Morrison VA. Phase III trial of rituximab-CHOP vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 102: 6a (Abstr).
8. Verdonck LF, Dekker AW, de Gast GC. Salvage therapy with Pro-MACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP. J Clin Oncol 1992; 10: 1949-1954.
9. Vose JM, Zhang Mei-Jie, Rowlings PA. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the autologousblood and marrow transplant registry. J Clin Oncol 2001; 19: 406-413.
10. Prince HM, Imrie K, Crump M et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic groups. Br J Haem 1996; 92: 880-889.
11. Saez R, Dahlberg S, Appelbaum FR et al. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: Southwest oncology group study. Hema Oncol 1994; 12: 75-85.
12. Nademanee A, Molin A, Dagis A. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 2000; 1: 45-54.
13. Salzman DE, Briggs AD, Vaughan WP. Bone marrow transplantation for non-Hodgkin's lymphoma: A review. Am J Med Sci 1997; 313: 228-235.
14. Kewalramani T, Zelenetz AD, Hedrick EE et al. High dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis. Blood 2000; 96: 2399-2404.
15. Philip T, Gugliemi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
16. Josting A, Reiser M, Rueffler U et al. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure? J Clin Oncol 2000; 18: 332-339.
17. Norton L, Simon R. The Norton-Simon hypothesis revisited. Canc Treat Rep 1986; 70: 163-169.
18. Gianni AM, Siena S, Bregni M et al. High-dose sequential chemoradiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - A 6-year update. Ann Oncol 1993; 4: 889-891.
19. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
20. Patrone F, Ballestrero A, Ferrando F et al. Four-step high-dose sequential chemotherapy with double hematopoetic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 1995; 13: 840-846.
21. Shea T, Mason JR, Storniolo AM et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocytemacrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992; 10: 464-473.
22. Gianni AM, Taella C, Bregni M et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994; 12: 503-509.
23. Caracciolo D, Gavarotti P, Aglietta M et al. High-dose sequential chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1993; 12: 621-625.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Cortelazzo S, Rambaldi A, Rossi A et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haem 2001; 114: 333-341.
26. Goldstone AH. High-dose therapy for the treatment of non-Hodgkin's lymphoma. In Armitage JO, Antman KH (eds): High-dose Cancer Theraphy: Pharmacology, Hematopoesis, Stem cells. Baltimore, MD, Williams and Wilkins 1995; 757-779.
27. Engert A, Josting A, Reiser M, Söhngen D, Diehl V. Aktueller Stellenwert der Hochdosistherapie in der Hämatologie und internistischen Onkologie. Med Klin 1999; 8: 431-442.
28. Josting A, Rudolph C, Reiser M et al. Time-intensified dexamethasone/ cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13: 1628-1635.
29. Zinzani PL, Tani M, Molinari AL et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/ refractory lymphoma patients. Haematologica 2002; 87: 816-821.
30. Engert A, Schnell R, Kupper F et al. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high-grade non-Hodgkin's lymphoma. Leuk Lymph 1997; 24: 513-522.
31. Reiser M, Schnell R, Straub G et al. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): An effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk Lymph 1998; 31: 359-366.
32. Rodriguez MA, Cabanillas FC, Velasquez W et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-1741.
33. Gianni AM, Bonadonna G. High-dose chemoradiotherapy for sensitive tumors: Is sequential better than concurrent drug delivery. Eur J Cancer Clin Oncol 1989; 25: 1027-1030.